Our findings suggest that vitamin B12 may be a potential therapeutic target for TDP-43-associated proteinopathies, and oral intake of Hb may be a potential therapeutic intervention for TDP-43-related ALS. The gene discussed is GSTM1; the disease is proteostasis deficiencies.